Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jorge E. Cortes, Donna E. Hogge, Martin S. Tallman, Tibor J. Kovacsovics, Lloyd E. Damon, Rami Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, Eric J. Feldman

Research output: Contribution to journal › Article › peer-review

286 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/ daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds